{"filing":{"accession_number":"0001671927-26-000020","cik":"0001671927","ticker":"IMCR","company_name":"Immunocore Holdings plc","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"imcr-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/imcr-20260806.htm"},"events":[{"id":25940,"run_id":23554,"accession_number":"0001671927-26-000020","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Immunocore's Q2 2026 financial results, including net product revenues of $115.9 million (18% YoY growth), R\u0026D and SG\u0026A expenses, net loss of $0.8 million, and cash position of $880.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the Company \"issued a press release announcing its financial results for the second quarter ended June 30, 2026.\" This is a material disclosure affecting investor assessment of the registrant's financial performance and operational progress.","company_name":"Immunocore Holdings plc","ticker":"IMCR","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26885,"accession_number":"0001671927-26-000020","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Immunocore's Q2 2026 financial results, including net product revenues of $115.9 million (18% YoY growth), R\u0026D and SG\u0026A expenses, net loss of $0.8 million, and cash position of $880.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the Company \"issued a press release announcing its financial results for the second quarter ended June 30, 2026.\" This is a material disclosure affecting investor assessment of the registrant's financial performance and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:48:28.418376+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26885,"accession_number":"0001671927-26-000020","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Immunocore's Q2 2026 financial results, including net product revenues of $115.9 million (18% YoY growth), R\u0026D and SG\u0026A expenses, net loss of $0.8 million, and cash position of $880.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the Company \"issued a press release announcing its financial results for the second quarter ended June 30, 2026.\" This is a material disclosure affecting investor assessment of the registrant's financial performance and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:48:28.418376+00:00","company_name":"Immunocore Holdings plc","ticker":"IMCR","filing_date":"2026-08-06"}]}